Cordant Inc’s Intellia Therapeutics NTLA Stock Holding History

Cordant Inc’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-116	Closed	-$825	–	89
2025 Q1	$825	Buy	+116	New	+$1.17K	﹤0.01%	103

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cordant Inc's NTLA Position: Q2 2025 in Review

Cordant Inc sold out of Intellia Therapeutics (NTLA) in Q2 2025, closing a stake of 116 shares — an estimated $825 sold.

Cordant Inc first reported a position in NTLA in Q1 2025 and held it in 1 quarter. The position peaked at $825 in Q1 2025. 280 funds tracked by Wall St. Rank hold NTLA as of Q2 2025.

Cordant Inc reported no remaining Intellia Therapeutics position as of Q2 2025 after selling out during the quarter.
Cordant Inc sold 116 Intellia Therapeutics shares in Q2 2025, an estimated $825.
Cordant Inc first reported a position in Intellia Therapeutics in Q1 2025 and held it in 1 quarter.
Cordant Inc's Intellia Therapeutics position peaked at $825 in Q1 2025.
280 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2025.

Based on Cordant Inc's 13F filing for Q2 2025, filed 15 Jul 2025.